The 441 Morgan Avenue development in Cambridge Crossing (Astellas)
August 9, 2023 07:30 PM EDT
Bioregnum

Astel­las builds its R&D foot­print in Cam­bridge/Boston with an add-on for labs, of­fices

Astel­las is snap­ping in an­oth­er piece of the re­al es­tate puz­zle for its glob­al R&D re­or­ga­ni­za­tion.

Just as it wraps one project to piece …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times